This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Data From Genzyme’s Multiple Sclerosis Franchise Featured At AAN

Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), announced today that 18 poster and oral presentations featuring Aubagio ® (teriflunomide) and Lemtrada TM (alemtuzumab) will be presented during the 66th American Academy of Neurology (AAN) Annual Meeting to be held in Philadelphia, April 26 – May 3, 2014.

As we continue to expand our global footprint in MS with product launches planned in more than 30 countries this year, we are proud to highlight the breadth and depth of our clinical development programs for Aubagio and Lemtrada at AAN,” said David Meeker, President and CEO, Genzyme. “ These new data will help to build a deeper understanding of MS and Genzyme’s treatments, and demonstrate our long-term commitment to meeting the needs of people living with MS.”

Presentations on Aubagio and Lemtrada at AAN are as follows, along with information about the Genzyme Corporate Therapeutic Update and Brain Health Fair sponsorship.

  • TOPIC: Efficacy and Safety of Once-Daily Oral Teriflunomide in Patients with First Clinical Episode Consistent With Multiple Sclerosis (Clinical Trials Plenary Session; May 2; 12:00 – 1:30 p.m. EDT)
  • Teriflunomide Does Not Significantly Affect Primary and Memory Antibody Responses to a Viral Antigen in Mice (Poster Session I – P1.215; April 28; 3:00 p.m. EDT)
  • Teriflunomide Treatment Is Not Associated With Increased Risk of Infections: Pooled Data From the Teriflunomide Development Program (Poster Session II – P2.194; April 29; 7:30 a.m. EDT)
  • Pooled Safety Data From Four Placebo-Controlled Teriflunomide Studies (Poster Session II – P2.203; April 29; 7:30 a.m. EDT)
  • Teriflunomide: Non-Clinical Evaluation Demonstrates No Effect On Sperm DNA or Male Fertility (Poster Session II – P2.233; April 29; 7:30 a.m. EDT)
  • Safety and Efficacy of Teriflunomide for up to 9 Years in Relapsing Forms of Multiple Sclerosis: Update of the TEMSO Extension Trial (Poster Session III – P3.150; April 29; 3:00 p.m. EDT)
  • Patients Free of Clinical MS Activity in TEMSO and TOWER: Pooled Analyses of Two Phase 3 Placebo-Controlled Trials (Poster Session III – P3.164; April 29; 3:00 p.m. EDT)
  • Updated Pregnancy Outcomes in Patients and Partners of Patients in the Teriflunomide Clinical Trial Program (Poser Session IV – P4.161; April 30; 7:30 a.m. EDT)
  • Estimating the Onset of Efficacy With Teriflunomide in Patients With Relapsing Forms of Multiple Sclerosis (Poster Session VII – P7.214; May 1; 3:00 p.m. EDT)

  • Treatment with Anti-mouse CD52 Antibody Is Associated with Preservation of Myelin and Maintenance of Axonal Conduction in the MOG-induced EAE Mouse Model (Poster Session I – P1.220; April 28; 3:00 p.m. EDT)
  • Anti-murine CD52 Antibody Treatment Does Not Adversely Affect the Migratory Ability of Immune Cells (Poster Session I – P1.222; April 28; 3:00 p.m. EDT)
  • Successful Detection and Management of Immune Thrombocytopenia in Alemtuzumab-Treated Patients with Active Relapsing-Remitting Multiple Sclerosis (Poster Session II – P2.198; April 29; 7:30 a.m. EDT)
  • Thyroid Autoimmune Adverse Events in Patients Treated with Alemtuzumab for Relapsing-remitting Multiple Sclerosis: Four-year Follow-up of the CARE-MS Studies (Poster Session II – P2.199; April 29; 7:30 a.m. EDT)
  • Safety of Using Disease-modifying Therapy Post-alemtuzumab Treatment in Patients With Relapsing-remitting Multiple Sclerosis in the Core and Extension Phases of CAMMS223, CARE-MS I, and CARE-MS II Studies (Poster Session II – P2.201; April 29; 7:30 a.m. EDT)
  • Alemtuzumab Has Similar Efficacy and Safety in Active Relapsing-Remitting Multiple Sclerosis (RRMS) Patients Who Were Treatment-Naive or Who Relapsed on Prior Therapy (Poster Session II – P2.209; April 29; 7:30 a.m. EDT)
  • Alemtuzumab Improves Visual Outcomes vs. Subcutaneous Interferon Beta-1a in Patients With Active Relapsing-Remitting Multiple Sclerosis (RRMS) Who Relapsed on Prior Therapy: Analysis From the CARE-MS II Study (Poster Session III – P3.158; April 29; 3:00 p.m. EDT; INS 7 Poster Rounds: Emerging Therapeutic Advances in Multiple Sclerosis – I7-1.010; April 30; 4:30 p.m. EDT)
  • Sustained Improvement in Disability Outcomes with Alemtuzumab in Active Relapsing-Remitting Multiple Sclerosis Patients Who Participated in CARE-MS II: Three-year Follow-up (Poster Session III – P3.165; April 29; 3:00 p.m. EDT)
  • Lymphocyte Counts Do Not Predict Risk of Subsequent Relapse or Disability Accumulation in Alemtuzumab-Treated Relapsing-Remitting Multiple Sclerosis Patients: An Analysis of the CARE-MS Studies (Poster Session III – P3.181; April 29; 3:00 p.m. EDT)

Abstracts are available on the AAN website.

1 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.21 -0.44%
FB $117.80 -0.22%
GOOG $701.26 0.80%
TSLA $211.34 -5.00%
YHOO $36.94 2.60%


Chart of I:DJI
DOW 17,660.71 +9.45 0.05%
S&P 500 2,050.63 -0.49 -0.02%
NASDAQ 4,717.0940 -8.5450 -0.18%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs